(Q40197232)

18 September 2017

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease (English)

1 reference

18 September 2017

0 references

1 reference

1 reference

1 reference

1 reference

Mehdi Gasmi

1

1 reference

18 September 2017

Christopher D Herzog

2

1 reference

18 September 2017

Eugene P Brandon

3

1 reference

18 September 2017

Justine J Cunningham

4

1 reference

18 September 2017

G Anthony Ramirez

5

1 reference

18 September 2017

Elias T Ketchum

6

1 reference

18 September 2017

Raymond T Bartus

7

1 reference

18 September 2017

1 January 2007

1 reference

18 September 2017

1 reference

18 September 2017

15

1 reference

18 September 2017

1

1 reference

18 September 2017

62-68

1 reference

Parkinson's disease. First of two parts

18 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Parkinson's disease. Second of two parts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Neurturin, a relative of glial-cell-line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

The potential of GDNF as a treatment for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Characterization of a multicomponent receptor for GDNF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

GFRalpha-2 and GFRalpha-3 are two new receptors for ligands of the GDNF family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Expression of neurturin, GDNF, and their receptors in the adult mouse CNS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Patterns of developmental mRNA expression of neurturin and GFRalpha2 in the rat striatum and substantia nigra do not suggest a role in the regulation of natural cell death in dopamine neurons.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Trophic factor distribution predicts functional recovery in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Genetic fate of recombinant adeno-associated virus vector genomes in muscle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Targeted retrograde gene delivery for neuronal protection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Efficient selection for high-expression transfectants with a novel eukaryotic vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300010

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300010

1 reference

18 September 2017

1 reference